Company Overview

Navin Fluorine International Limited (BSE: 532504, NSE: NAVINFLUOR) reported exceptional financial performance for FY 2025-26, demonstrating robust growth across all key metrics with significant margin expansion and strategic capacity enhancements.

Financial Performance Highlights

Consolidated Results:

  • Revenue from Operations: ₹3,313.90 crores (41.05% YoY growth from ₹2,349.38 crores)
  • Operating EBITDA: ₹1,081.68 crores (102.67% YoY growth) with margin expansion of 992 bps to 32.64%
  • Net Profit: ₹663.55 crores (129.94% YoY growth from ₹288.58 crores) with net margin of 20.02%
  • Return on Capital Employed: 25.92%
  • Basic EPS: ₹130.66 (FY25: ₹58.20)

Standalone Results:

  • Revenue from Operations: ₹2,301.84 crores (36.46% YoY growth)
  • Net Profit: ₹487.67 crores (101.54% YoY growth)
  • Book Value per Share: ₹775.55 (FY25: ₹529.59)

Capital Structure & Fundraising

  • Successfully raised ₹750 crores through Qualified Institutional Placement (QIP) in July 2025, issuing 16,02,564 equity shares at ₹4,680 per share
  • Funds utilized for debt repayment (₹562.50 crores), general corporate purposes (₹170.75 crores), and issue expenses (₹16.75 crores)
  • Net debt-equity improved significantly to 0.01 from 0.37, achieving near net cash position
  • Maintained CARE AA credit rating for long-term borrowings and CARE A1+ for short-term facilities

Business Segment Performance

High Performance Products (HPP): ₹1,615.38 crores (33.93% growth), contributing 48.75% of total revenue with new 40,000 MTPA AHF capacity commissioned at Dahej

Specialty Chemicals: ₹1,152.09 crores (43.94% growth), contributing 34.76% of revenue with strategic partnership with Chemours for Opteon™ immersion cooling fluid

CDMO Business: ₹546.43 crores (59.39% growth), contributing 16.49% of revenue with successful commissioning of cGMP4 Phase 1 facility at Dewas

Manufacturing Expansion & Capex

  • Commissioned new AHF plant at Dahej (40,000 MTPA capacity)
  • Ramped up second R-32 plant at Surat
  • Operationalized cGMP4 Phase 1 block at Dewas and fluoro-specialty plant at Dahej
  • Board approved capex of ₹236.50 crores for additional 15,000 MTPA R32 capacity and ₹75 crores for MPP debottlenecking
  • Capital commitments of ₹270.47 crores for property, plant and equipment

ESG & Sustainability Performance

  • Renewable Electricity: 12.15% of total consumption (58,010.03 GJ)
  • Water Recycled: 6,85,418.00 KL (54.31% of total withdrawal)
  • Waste Recycled: 87,902.03 MT (65.76% recycling rate)
  • GHG Emissions: Scope 1 - 1,54,883.30 tCO₂e, Scope 2 - 84,665.97 tCO₂e
  • 16% reduction in energy consumption year-over-year
  • Completed inaugural TCFD-aligned Climate Risk Assessment
  • ISO/IEC 27001 certification for Information Security Management System
  • Zero liquid discharge implemented at Dewas manufacturing facility

Corporate Governance & Board Structure

  • 10-member Board with 6 Independent Directors (60% independence)
  • 97.50% average Board attendance in FY26
  • Women representation: 1 Director on Board, 3.94% women employees
  • Director remuneration: ₹17.06 crores for Executive Chairman, ₹12.47 crores for Managing Director
  • 4 out of 6 Board committees chaired by Independent Directors
  • Shareholding pattern: Promoters 27.11%, FPI Category I 23.77%, Mutual Funds 18.40%

Dividend & Corporate Actions

  • Interim Dividend: ₹6.50 per share (paid November 2025)
  • Final Dividend Recommended: ₹8.60 per share (430% of face value)
  • Total Dividend for FY26: ₹15.10 per share
  • Record Date: June 12, 2026 | Payment Date: On or after August 13, 2026
  • 28th Annual General Meeting scheduled for August 6, 2026 via video conferencing

Employee Benefits & ESOP

  • ESOP activity: 55,885 options exercised at weighted average exercise price of ₹2,411.00
  • Share-based payment expenses: ₹4.82 crores (FY25: ₹11.51 crores)
  • Exceptional item of ₹6.93 crores recognized for restructuring employee emoluments to align with new Labour Codes
  • Total employees: 1,045 across company and subsidiaries
  • Attrition rate: 15.90% for permanent employees

Investments & Subsidiaries

  • Investment properties independently valued at ₹189.07 crores (carrying amount: ₹37.27 crores)
  • Investments in subsidiaries and joint venture: ₹1,143.69 crores
  • Current investments (primarily mutual funds): ₹1,210.40 crores
  • Key subsidiaries: Navin Fluorine Advanced Sciences Limited, Manchester Organics Limited, Sulakshana Securities Limited
  • Joint venture: Swarnim Gujarat Fluorspar Private Limited (49.48% ownership)

Risk Management & Compliance

  • Comprehensive Risk Management Framework with regular reporting to Risk Management Committee and Board
  • No penalties or strictures imposed by Stock Exchanges, SEBI or statutory authorities
  • Contingent liabilities: ₹8.87 crores across various tax and regulatory matters
  • Internal audit conducted by independent firm with transition to SAP S/4HANA completed
  • Compliance with SEBI LODR Regulations, Companies Act 2013, IFRS Foundation's Integrated Reporting Framework

CSR Initiatives

  • Total CSR spend: ₹7.50 crores (exceeding mandatory requirement of ₹6.47 crores)
  • Key partners: Shri Sadguru Seva Sangh Trust (₹3.00 crores), Blind People's Association (₹1.45 crores), Charutar Arogya Mandal (₹1.20 crores)
  • Mobile Health Vans operating around Dewas and Surat plants
  • Impact assessment voluntarily conducted for projects

Auditor Information

  • Statutory Auditors: Price Waterhouse Chartered Accountants LLP
  • Cost Auditors: Makarand M. Joshi and Co.
  • Secretarial Auditors: Parikh & Associates
  • ESG Assurance: TUV SUD South Asia Pvt. Ltd.

Forward Outlook

The company maintains strong growth momentum with expanded capacities, reduced debt burden, and strategic focus on high-value segments. Continued investment in sustainability initiatives and regulatory compliance positions Navin Fluorine for sustained performance in the specialty chemicals and pharmaceutical CDMO sectors.